Anti‐PD‐(L)1 therapy has changed the treatment landscape for a variety of solid tumor types, including NSCLC, melanoma, squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and urothelial carcinoma (UC), due to higher response rates and more manageable toxicity profiles than chemotherapy. Here, CD274 is linked to renal cell carcinoma.